Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
See the FAQ tab for more information
Wegovy and Zepbound are GLP-1 medications that are FDA-approved to treat obesity
It also slows down digestion, reduces appetite, and increases insulin release
Mounjaro users, meanwhile, lost an average of 20.2%
Pay attention to how your body feels and stop eating once you feel full
After the initial 36 weeks, participants lost 21.1% of their body weight After the following 52 weeks, the tirzepatide group lost another 6.7% of their body weight, while the placebo group regained 14.8% Through the 88-week study, the tirzepatide group lost 26% of their body weight Tirzepatide had a similar safety profile in SURMOUNT-3 and SURMOUNT-4 as its previous trials, most commonly citing mild-moderate gastrointestinal issues
